In a 58-year-old male with hypertension and rheumatoid arthritis treated with methotrexate and hydroxychloroquine, who has progressive dyspnea over three months, resting oxygen saturation of 92%, fine inspiratory crackles at the lung bases, and abnormal pulmonary function tests after normal complete blood count, comprehensive metabolic panel, and electrocardiogram, what is the next appropriate diagnostic test to order?

High-Resolution CT Chest (HRCT) is the Next Appropriate Test

In this patient with rheumatoid arthritis on methotrexate presenting with progressive dyspnea, desaturation on exertion, and basilar crackles with abnormal PFTs, you should order a high-resolution CT chest immediately to differentiate between RA-associated interstitial lung disease (RA-ILD) and methotrexate-induced pneumonitis.

Clinical Reasoning

This 58-year-old male presents with a classic triad that demands urgent evaluation:

• Progressive dyspnea over 3 months with exertional desaturation (92% at rest, dropping to 88% with ambulation)
• Fine inspiratory crackles at lung bases
• Abnormal pulmonary function tests
• Rheumatoid arthritis on methotrexate and hydroxychloroquine

The 2023 ACR/CHEST guideline specifically recommends HRCT chest over PFTs alone for screening in patients with systemic autoimmune rheumatic diseases at increased risk of ILD 1. The guideline states HRCT has 95.7% sensitivity for detecting ILD with ≥20% lung involvement, making it superior to history, physical examination, or PFTs alone 1.

Why HRCT Over Other Tests

The ACR Appropriateness Criteria (2025) for chronic dyspnea designates chest CT as the primary imaging modality for evaluating noncardiovascular chronic dyspnea, particularly when interstitial lung disease is suspected 2. Standard chest radiography is inadequate—the 2023 guideline conditionally recommends against monitoring with chest radiography in SARD-ILD 1.

Critical Differential: Two Life-Threatening Possibilities

This patient faces two distinct but overlapping pulmonary complications:

1. RA-Associated Interstitial Lung Disease (RA-ILD): Occurs in 3-5% of RA patients 1. His risk factors include:

   • Male sex
   • Significant smoking history (28 pack-years)
   • Age >50 years
   • Progressive symptoms over months

2. Methotrexate-Induced Pneumonitis: An idiosyncratic hypersensitivity reaction that can occur at any time during therapy 345. The FDA label warns that "pulmonary symptoms (especially a dry nonproductive cough) or nonspecific pneumonitis occurring during methotrexate therapy may be indicative of a potentially dangerous lesion and require interruption of treatment" 3.

HRCT is essential because it can distinguish these entities: RA-ILD typically shows usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP) patterns with basilar predominance, while methotrexate pneumonitis often presents with ground-glass opacities, sometimes with a more diffuse distribution 46.

Imaging Specifications

Order HRCT chest without contrast with the following protocol 1:

• Thin-slice reconstruction (<1.5 mm)
• Inspiratory prone images (to differentiate dependent atelectasis from early fibrosis)
• Supine end-expiratory imaging (to assess for air-trapping)
• Low-dose technique is adequate

Contrast is unnecessary unless there's concern for pulmonary vascular disease or chest wall involvement 2.

Critical Management Considerations

If Methotrexate Pneumonitis is Suspected:

The FDA label is explicit: "discontinue methotrexate and monitor the patient closely" when pulmonary toxicity is suspected 3. Recent case reports demonstrate that methotrexate pneumonitis can present acutely and requires prompt recognition 456. Treatment involves:

• Immediate methotrexate cessation
• High-dose corticosteroids
• Prognosis is generally favorable with early intervention 4

If RA-ILD is Confirmed:

The 2023 guideline recommends monitoring with PFTs every 3-12 months for RA-ILD patients 1. However, methotrexate may need to be discontinued given the FDA warning about using it in patients with preexisting lung disease 3.

Common Pitfalls to Avoid

1. Don't wait for worsening symptoms: The patient already has resting hypoxemia (92%) and significant exertional desaturation—this represents moderate-to-severe impairment requiring urgent evaluation.

2. Don't assume it's one or the other: Patients can have both RA-ILD and superimposed drug toxicity. One case report described how methotrexate and tacrolimus actually masked hypersensitivity pneumonitis symptoms 7.

3. Don't order a standard chest CT: Specifically request HRCT with the protocol above. Standard CT may miss early fibrotic changes 1.

4. Don't continue methotrexate pending workup: Given the FDA's explicit warning and the severity of presentation, strongly consider holding methotrexate until HRCT results clarify the diagnosis 3.

5. Hydroxychloroquine consideration: While less commonly implicated in pneumonitis, recent data suggests hydroxychloroquine may be associated with higher ILD risk compared to methotrexate in some populations 8, though this remains controversial and requires cautious interpretation.

Next Steps After HRCT

Based on HRCT findings, you may need:

• Bronchoalveolar lavage if the diagnosis remains unclear (increased lymphocytes suggest hypersensitivity pneumonitis) 7
• Transbronchial or surgical lung biopsy for definitive diagnosis if imaging is equivocal
• Rheumatology and pulmonology co-management for treatment decisions

The guideline recommends against routine bronchoscopy for monitoring but acknowledges its role when clinically indicated for diagnosis 1.